SicaGene
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SicaGene - overview
Established
2021
Location
Beijing, Beijing, China
Primary Industry
Biotechnology
About
Established in 2021 and based in Beijing, China, Sica Gene (Beijing) Biotechnology Co. , Ltd. , doing business as SicaGene, is an oligonucleotide drug research and development company. In February 2025, it closed a venture funding from new investor Beijing Baiyang Zhongxin Kangjian Investment Management.
The company’s main business is developing next-generation antisense oligonucleotide (ASO) therapeutics. The company’s self-developed products include the SicaScreen™ AI-powered sequence screening platform, SicaChemistry™ nucleic acid combinatorial modification technology, and SicaDelivery™ multi-tissue targeting system. Its products are used in the field of central nervous system (CNS) disorders, ophthalmology, liver diseases, and viral infections. The company generates revenue by licensing its proprietary ASO platform to pharmaceutical partners and by providing diagnostic services and equipment leasing.
Current Investors
MSA Capital, Beijing Baheal Zhongxin Kangjian Investment Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.sicagene.com/
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.